Meeting
2020 ASCO Virtual Scientific Program
Anaplastic lymphoma kinase (ALK) partners identified by next-generation sequencing in Chinese patients with solid tumors.
Authors
Sheng Yang
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
Sheng Yang , Fuyu Gong , Guoqiang Wang , Xiaohui He
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Molecular Diagnostics and Imaging
Citation
J Clin Oncol 38: 2020 (suppl; abstr 3555)
DOI
10.1200/JCO.2020.38.15_suppl.3555
Abstract #
3555
Poster Bd #
285
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Genetic landscape of ALK+ non-small cell lung cancer (NSCLC) patients (pts) and response to ceritinib in ASCEND-1.
First Author: Daniel Shao-Weng Tan
Poster
2020 ASCO Virtual Scientific Program
Longitudinal monitoring by next generation sequencing of plasma cell-free DNA in ALK-rearranged non-small cell lung cancer (NSCLC) patients treated with ALK tyrosine kinase inhibitors.
First Author: Minsuk Kwon
Poster
2017 ASCO Annual Meeting
Parallel VENTANA IHC and RT-PCR of ALK status in non-small cell lung cancer and response to crizotinib.
First Author: Chunwei Xu
Poster
2014 ASCO Annual Meeting
Identifying ALK rearrangements that are not detected by FISH with targeted next-generation sequencing of lung carcinoma.
First Author: Siraj M. Ali